- Home
- TERN vs AB Comparison
TERN vs AB Comparison
Compare TERN & AB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TERN | AB |
|---|---|---|
| Founded | 2017 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.7B |
| IPO Year | 2021 | 1988 |
Fundamental Metrics
Financial Performance| Metric | TERN | AB |
|---|---|---|
| Price | $34.33 | $41.34 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 5 |
| Target Price | ★ $48.60 | $41.60 |
| AVG Volume (30 Days) | ★ 2.1M | 349.8K |
| Earning Date | 03-19-2026 | 02-05-2026 |
| Dividend Yield | N/A | ★ 7.66% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.03 |
| Revenue | ★ N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $8.72 |
| P/E Ratio | ★ N/A | $14.03 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.87 | $32.28 |
| 52 Week High | $48.26 | $44.11 |
Technical Indicators
Market Signals| Indicator | TERN | AB |
|---|---|---|
| Relative Strength Index (RSI) | 42.71 | 56.76 |
| Support Level | $33.60 | $38.55 |
| Resistance Level | $35.46 | $44.11 |
| Average True Range (ATR) | 1.93 | 1.26 |
| MACD | -0.56 | 0.36 |
| Stochastic Oscillator | 18.52 | 53.08 |
Price Performance
Historical ComparisonAbout TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
About AB AllianceBernstein Holding L.P.
AllianceBernstein provides investment management services to institutional (41% of assets under management), retail (42%), and private (17%) clients through products that includes mutual funds, hedge funds, and separately managed accounts. At the end of July 2025, the company had $829 billion in managed assets, composed primarily of fixed-income (36% of AUM) and equity (42%) strategies, with other investments (made up of asset allocation services and certain other alternative investments) accounting for the remainder.